Barclays’s Inovio Pharmaceuticals INO Stock Holding History

Barclays’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-833	Closed	-$89K	–	4938
2020 Q4	$89K	Sell	833 -1,667	-67%	-$222K	﹤0.01%	4178
2020 Q3	$348K	Sell	2,500 -1,667	-40%	-$348K	﹤0.01%	3486
2020 Q2	$1.35M	Buy	+4,167	New	+$669K	﹤0.01%	2483

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Quadrature Capital London, United Kingdom $16.1B AUM 61.25% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

Barclays's INO Position: Q3 2026 in Review

Barclays reduced its Inovio Pharmaceuticals (INO) stake by 19% in Q3 2026, selling an estimated $737 and leaving 2,826 shares worth $3.45K. The position accounts for ﹤0.01% of the portfolio, ranked #4922.

Barclays first reported a position in INO in Q4 2013 and has held it in 49 quarters since. The position peaked at $7.02M in Q2 2020. 79 funds tracked by Wall St. Rank hold INO as of Q3 2026.

Barclays held 2,826 shares of Inovio Pharmaceuticals worth $3.45K as of Q3 2026.
Barclays sold 661 Inovio Pharmaceuticals shares in Q3 2026, an estimated $737.
Inovio Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4922 holding.
Barclays first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
Barclays's Inovio Pharmaceuticals position peaked at $7.02M in Q2 2020.
79 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.